---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-002405"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:39:15.151047+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics appoints Claire Fraser, Ph.D. as Class II director and to Audit Committee

## Summary
- Board expanded to ten directors; Dr. Fraser appointed as Class II director and to Audit Committee.
- Standard non-employee director compensation: $45,000 annual retainer, $10,000 audit committee retainer.
- Initial option grant: 48,000 shares at $5.47 exercise price, vesting over four years or upon change in control.
- Entered into standard director and officer indemnification agreement.

## SEC filing metadata
- accession: 0001193125-23-002405
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/0001193125-23-002405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/d436852d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-002405
- JSON: https://secwatch.observer/filing/0001193125-23-002405.json
- Plain text: https://secwatch.observer/filing/0001193125-23-002405.txt

## Key facts
- Executive change
  Claire Fraser was appointed as Class II Director at Seres Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On January 4, 2023, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) increased its size to provide for a total of ten directors authorized to serve on the Board and appointed Claire Fraser, Ph.D. as a Class II director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609809/000119312523002405/0001193125-23-002405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.